Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

Vaccine

Volumn 21, Issue 1-2, 2002, Pages 30-43

  Santos, Wania Renata ^a   De Lima, Valeria M F ^b   De Souza, Edilma Paraguai ^a   Bernardo, Robson Ronney ^a   Palatnik, Marcos ^a   De Sousa, Clarisa Beatriz Palatnik ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Adjuvants; IL12; Murine visceral leishmaniasis; QS21; QuilA; Saponin

Indexed keywords

BCG VACCINE; FML ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LEISHMANIA VACCINE; PARASITE ANTIGEN; QS21 SAPONIN; QUILA SAPONIN; RIEDEL DE HAEN SAPONIN; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG; PROTOZOAL VACCINE; SAPONIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE MODEL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; LEISHMANIA DONOVANI; LIVER; MOUSE; NONHUMAN; NORMAL HUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VACCINATION; VISCERAL LEISHMANIASIS; ANIMAL; IMMUNOLOGY; MYCOBACTERIUM BOVIS; PARASITOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; INTERLEUKIN-12; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MICE; MYCOBACTERIUM BOVIS; PROTOZOAN VACCINES; SAPONINS;

EID: 0037159626     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00444-9     Document Type: Article

References (57)

1. Momen H., Grimaldi Junior G., Deane L.M. Leishmania infantum, the aetiological agent of American visceral leishmaniasis (AVL)? Mem. Inst. Oswaldo Cruz. 82:1987;447-448.
2. Cunha A.M. Experimental infection in American visceral leishmaniasis. Mem. Inst. Oswaldo Cruz. 33:1938;581-616.
3. Mauricio I.L., Stothard J.R., Miles M.A. The strange case of Leishmania chagasi. Parasitol. Today. 16:2000;188-189.
4. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55:1996;125-130.
5. Convit J., Castellano P.L., Rondon A., Penardi M.E., Ulrich M., Castes M.et al. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis. Lancet. 1:1987;401-404.
6. Castes M., Backwell J., Trujillo D., Formica S., Cabrera M., Zorrilla G.et al. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I. Skin-test reactivity, T-cell proliferation and interferon-γ production. Vaccine. 12:1994;1041-1051.
7. Bahar K, Shidani B, Dowlati Y, Deihimi I, Fesharki R, Ale-Agha S, et al. Overview of human vaccine studies using killed L. major. In: Proceedings of the 13th International Congress for Tropical Medicine and Malaria Faculty of Tropical Medicine, Mahidol University, Bankok [abstracts 1993;1:183].
8. Nascimento E., Mayrink C.A., Da Costa C.A., Michalick M.S.M., Melo M.N., Barros G.C.et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune response. Infect. Immun. 58:1990;2198-2203.
9. Antunes C.M., Mayrink W., Magalhães P.A., Costa A., Melo M.N., Dias M.et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int. J. Epidemiol. 15:1986;572-580.
10. Santos W.R., Paraguai de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination with the FML antigen (Fucose Mannose Ligand) of Leishmania donovani in the Swiss Albino model. Vaccine. 17:1999;2554-2561.
11. Maingon R., Le Ray D., Hommel M. Leishmaniasis research and the European Union. Parasitol. Today. 11:1995;357-359.
12. Khalil E.A.G., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B.et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double blind, BCG-controlled trial in Sudan. Lancet. 356:2000;1565-1569.
13. Cruz A., Coburn C.M., Beverley S.M. Double targeted gene replacement for creating null mutants. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7170-7174.
14. McMahon-Pratt D., Rodriguez D., Rodriguez J.R., Zhang Y., Manson K., Bergman C.et al. Recombinant vaccinia viruses expressing GP-46/M-2 protect against Leishmania infection. Infect. Immun. 61:1993;3351-3359.
15. Yang D.M., Fairweather N., Button L.L., McMaster W.R., Kahl L.P., Liew F.Y. Oral Salmonella typhimurium (AroA) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 145:1990;2281-2285.
16. Skeiky Y.A.W., Guderian J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M.et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181:1995;1527-1537.
17. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania donovani. J. Exp. Med. 186:1997;1137-1147.
18. Jardim A., Tolson D.L., Turco S.J., Pearson T.W., Olafson R.W. The Leishmania donovani lypophosphoglycan T lymphocyte reactive component is a tightly associated protein complex. J. Immunol. 147:1991;3538-3544.
19. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:1993;2322-2331.
20. Palatnik C.B., Borojevic R., Previato J.O., Mendonça-Previato L. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect. Immun. 57:1989;754-763.
21. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine. 12:1994;1534-1536.
22. Palatnik de Sousa C.B., Dutra H.S., Borojevic R. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose Mannose Ligand (FML). Acta Trop. 53:1993;59-72.
23. Palatnik C.B., Previato J.O., Mendonça-Previato L., Borojevic R. A new approach to phylogeny of Leishmania: species-specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasitol. Res. 76:1990;289-293.
24. Palatnik de Sousa C.B., Paraguai de Souza E., Gomes E.M., Borojevic R. Experimental murine Leishmania donovani infection: immunoprotection by the Fucose Mannose Ligand (FML). Braz. J. Med. Biol. Res. 27:1994;547-551.
25. Palatnik de Sousa C.B., Gomes E.M., Paraguai de Souza E., Luz K., Palatnik M., Borojevic R. Leishmania donovani: titration of antibodies to the Fucose Mannose Ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg. 89:1995;390-393.
26. Borja-Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O.et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am. J. Trop. Med. Hyg. 61:1999;296-301.
27. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., Borojevic R. The FML vaccine (Fucose-Mannose Ligand) protects hamsters from experimental kala-azar. Ciência e Cultura (J. Braz. Assoc. Adv. Sci.). 46:1994;290-296.
28. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M.et al. A Phase III trial of Efficacy of the FML- vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 19:2001;1068-1081.
29. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M.et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 20:2002;3277-3284.
30. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R.et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS21. Vaccine. 19:2001;3957-3967.
31. Garcez dos Santos Silveira LM. Induction of Immunity Induction Against Infection Leishmania (Leishmania) Amazonensis in Cebus Apella Primate. Ph.D. Thesis. Biology of the Pathogen-Host Relationships Program, Institute for Biomedical Sciences, University of São Paulo, 2000.
32. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12n and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:1999;4481-4488.
33. Kensil C.R., Patel U., Lennick M., Marciani D.J. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:1991;431-437.
34. Santos W.R., Bernado R.R., Peçanha L.T., Palatnik M., Parente J.P., Palatnik de Sousa C.B. Hemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine. 15:1997;1024-1029.
35. Dwyer D.M. Leishmania donovani: surface membrane carbohydrates of promastigotes. Exp. Parasitol. 41:1977;341-358.
36. Turco S.J., Wilkerson M.A., Clawson D.R. Expression of an unusual acidic glycoconjugate in Leishmania donovani. J. Biol. Chem. 259:1984;3883-3889.
37. Sacks D.L., Modi G., Rowton E., Spath G., Epstein L., Turco S.J.et al. The role of phosphoglycans in Leishmania-sand fly interactions. Proc. Natl. Acad. Sci. U.S.A. 97:2000;406-411.
38. Luz K.G., Gomes E.M., da Silva V.O., Machado F.C.S., Araújo M.A.F., Fonseca H.E.M.et al. Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and polytransfused hemodialyzed patients. Am. J. Trop. Med. Hyg. 57:1997;168-171.
39. Hancock G.E., Speeelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune response in Balb/c mice that are similar to those generated by experimental infection. Vaccine. 13:1995;391-400.
40. Wu J.Y., Gardner B., Murphy C.I.et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 148:1992;1519-1525.
41. Britt W., Fay J., Kensil C. Formulation of an immunogenic human cytomegalovirus vaccine: response in mice. J. Infect. Dis. 171:1995;18-25.
42. Aebischer T., Wolfram M., Patzer S.I., Ilg T., Wiese M., Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect. Immun. 68:2000;1328-1336.
43. Marciani D.J., Pathak A.K., Reynolds R.C., Seitz L., May R.D. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 1:2001;813-818.
44. Oda K., Matsuda H., Murakami T., Katajama S., Oghitani T., Yoshikawa M. Adjuvant and hemolytic activities of 47 saponins derived from medicinal and food plants. Biol. Chem. 381:2000;67-74.
45. Takechi M., Tanaka Y. Hemolytic time course differences between steroid and triterpenoid saponins. Planta Med. 61:1995;76-77.
46. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R., Newman M.J.et al. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 12:1994;1275-1280.
47. Keefer M.C., Wolff M., Gorse G.J.et al. Safety profile of Phase I trial and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 13:1997;1163-1177.
48. Stoute J.Á., Slaoui M., Heppner D.G.et al. A preliminary evaluation of a recombinant circumsporozoite vaccine against Plasmodium falciparum malaria. New Eng. J. Med. 9:1997;86-91.
49. Sharifi I., FeKri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R.A.et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 351:1998;1540-1543.
50. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Dowlati Y.et al. A randomised, double blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis. Vaccine. 17:1999;266-272.
51. Doherty T.M., Coffman R.L. Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL-12 production. Eur. J. Immunol. 29:1999;522-529.
52. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C.et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-γ dependent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 8:1999;6970-6975.
53. Ahujaddick R.L., Sato N., Montalbo E., Kostecki V., Zhao W., Dolan M.J.et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163:1999;3890-3897.
54. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:2001;4719-4725.
55. Schetters T.P.M., Kleuskens J., Scholtes N., Bos H.J. Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture. Parasite Immunol. 14:1992;295-305.
56. Bomford R., Stapleton M., Winsor S., McNight A., Andronova T. The control of the antibody isotype response to recombinant immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Hum. Retroviruses. 8:1992;1765-1771.
57. Cox S.J., Barnett P.V., Dani P., Salt J.S. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 17:1999;1858-1868.